
Upadacitinib achieves 50% reduction in Total Vitiligo Area Scoring Index at 48 weeks
A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.



























